Psyence Group Inc. (PSYGF)
OTHER OTC:PSYGF
PSYGF Stock Chart & Stats
$0.13
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$0.10 - $0.14
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$1.32M
Enterprise Value$1.35M
Total Cash (Recent Filing)$528.11K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta3.74
Next Earnings
Aug 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding15,638,267
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.43
Price to Sales (P/S)0.00
P/FCF Ratio-0.33
Enterprise Value/Market Cap1.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-203.88
Enterprise Value/Ebitda-0.08
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic Growth InitiativesThe share consolidation aims to provide greater flexibility for business development and growth, potentially improving market positioning and stakeholder interests.
Enhanced Research CapabilitiesAppointing a new chair enhances research capabilities in psilocybin-based treatments, supporting long-term development and innovation in psychedelic therapeutics.
Scientific Advisory Board ExpansionStrengthening the Scientific Advisory Board with a leader in psychopharmacology supports ongoing clinical trials and enhances the company's positioning in the psychedelic therapeutics industry.
Bears Say
Financial InstabilityThe company's financial instability, marked by persistent losses and negative equity, poses significant risks to its ability to sustain operations without external support.
Cash Flow IssuesPoor cash flow management and reliance on external funding indicate liquidity concerns, which could hinder the company's long-term financial health and operational sustainability.
Lack Of Revenue GenerationThe absence of revenue generation and negative profit margins reflect stagnant financial performance, challenging the company's ability to achieve profitability and sustain growth.
Psyence Group News
PSYGF FAQ
What was Psyence Group Inc.’s price range in the past 12 months?
Psyence Group Inc. lowest stock price was $0.10 and its highest was $0.14 in the past 12 months.
What is Psyence Group Inc.’s market cap?
Psyence Group Inc.’s market cap is $1.32M.
When is Psyence Group Inc.’s upcoming earnings report date?
Psyence Group Inc.’s upcoming earnings report date is Aug 04, 2026 which is in 43 days.
How were Psyence Group Inc.’s earnings last quarter?
Psyence Group Inc. released its earnings results on Mar 02, 2026. The company reported -$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.003.
Is Psyence Group Inc. overvalued?
According to Wall Street analysts Psyence Group Inc.’s price is currently Undervalued.
Does Psyence Group Inc. pay dividends?
Psyence Group Inc. does not currently pay dividends.
What is Psyence Group Inc.’s EPS estimate?
Psyence Group Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Psyence Group Inc. have?
Psyence Group Inc. has 15,638,267 shares outstanding.
What happened to Psyence Group Inc.’s price movement after its last earnings report?
Psyence Group Inc. reported an EPS of -$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Psyence Group Inc.?
Currently, no hedge funds are holding shares in PSYGF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Psyence Group Inc.
Psyence Group Inc. is a life sciences biotechnology company primarily engaged in the commercial cultivation and production of psilocybin mushrooms. This naturally sourced psilocybin is intended for therapeutic applications, addressing a broad spectrum of mental health conditions and other medical ailments. The company is actively formulating pharmaceutical-grade psilocybin treatments designed to mitigate psychological trauma and recognized disorders such as anxiety, depression, post-traumatic stress disorder (PTSD), and the emotional distress linked to grief and bereavement. Furthermore, Psyence Group develops, distributes, and sells over-the-counter functional mushroom nutraceuticals, entirely free of psilocybin, under its GOODMIND brand. Established in 2019, the company maintains its headquarters in Toronto, Canada.
Ownership Overview
Options Prices
Currently, No data available
---